From startup to scaleup

Drs. Hans Platteeuw

Avivia History

• In 2005 Avivia started as a one-man company focussing on providing consultancy services in pharmaceutical product development

• In 2007 the company was restructured into a limited liability company and the first personnel was hired

• In 2010 the decision was taken to scale down the consultancy business and start investing in our own ideas and on setting up joint ventures with other SME-companies

The opportunity to take the next step

• In 2013, Synthon announced that it would close down its small molecule development activitities in Nijmegen, The Netherlands

• Several people saw this as an opportunity to make the change from being an employee to becoming an entrepeneur

• In 2014, we started working together and through SMB we hired a business consultant, Peter van de Laarse, to advice us on how best to setup a combined business

Getting the basics right for Avivia 2.0

• Avivia 2.0 is a merger between 3 new one-man companies with an inventory of equipment and an established company with a network, running business and development projects

• Main issues that needed to be adressed: - what assets does each individual company bring to the table

- what is the value of those assets within the new company

- how does that translate into the total value of the company and the distribution of shares

- what is the optimal legal and fiscal setup for the new company

- who will lead the new company

- financial forecast and business plan (with a 7-year horizon)

- we have setup the control systems for our business, like the financial, project and contract administration and time allocation

• Avivia 2.0 was legally formed on the 14th of July, 2015

Avivia Team

Slide

5

Within Avivia we have the capabilities and the

expertise to develop any pharmaceutical drug

product from scratch to cGMP

Menno Wiltink

Synthon

Analytical development

Hans Platteeuw

Synthon, Dafra, Avivia

Managing Director Dennie van den Heuvel

Intervet, Synthon

Pharmaceutical Development

Hans van der Steen

CP Kelco, Synthon

Analytical Research

Thomas Verbeek

AUV veterinary

services

Controller

Marleen De Vriese

Dafra, Avivia

Project Manager

Avivia Professional Panel

Slide

6

In our operations we have close ties with a number

of professionals that work with us on a daily

basis in various aspects of our business.

Wout Wouters

Solvay, TNO, Pantarhei

In vitro testing and in

vivo animal studies

Han van ‘t Klooster

Pharmacytics, Chamaeleo

Business developmentLaurens Theunis

Galapagos, Formac, Chamaeleo

Investment manager

Frank Vanderdonck

Pfizer, UCB, Ipsen,

Chamaeleo

Business Intelligence/Medical

Liaison Peter van de Laarse

PWC, Belastingdienst

Business Consultant

Gelein Platteeuw

Intervet/MSD

Facilities/Procurement

Avivia business

• Avivia has developed a number of opportunities for repurposingof existing drugs in various clinical fields, e.g. GastrointestinalInflammation, Womens’ Health, Oncology and Tropical Diseases

• We currently have 2 products in a screening stage, 3 in feasilibity and 4 in proof of concept testing (phase II clinical testing in patients/volunteers)

• We are also open for other companies to support them in their product developments, either as a pure fee for service (contract research) or in co-development deals

Slide

7

Avivia within 5 years

• Within 5 years aim to become a flexible, dedicated, creative pharmaceutical product innovation company with a focus on drug repurposing programs

• We expect to employ 20-25 people and have an annual turnover of at least 10 million Euro

For more information, please contact:

9

Hans Platteeuw

Van Leeuwenhoekweg 12

5482 TK Schijndel

The Netherlands

Mobile: + 31 6 286 75 973

E-mail: hansplatteeuw@avivia.nl

Skype: hans.platteeuw